BRCA1 and BRCA2 ▲ Public Health Genomics Knowledge Base (v1.2)

Public Health Genomics Knowledge Base (v1.2)






Last Updated: Nov 03, 2016

• Clinical and Pathological Characteristics of Incidental Diagnostic Early Occult Malignancy After Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers.
  Lavie Ofer et al. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2016 Feb 26(2) 233-9
• Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
  Egloff Heidi et al. Cancer investigation 2016 Oct 1-5
• Learn About Hereditary Pancreatic Cancer
  L Rezende, Facing Our Risk Empowered, November 1, 2016
• Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
  Badoer Cindy et al. Oncotarget 2016 Oct
• Reproductive Decision-Making in Women with BRCA1/2 Mutations.
  Chan Jessica L et al. Journal of genetic counseling 2016 Oct
• Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
  Moran Olivia et al. Breast cancer research and treatment 2016 Oct
• http://www.mdedge.com/jcso/article/110048/gynecologic-cancer/hereditary-breast-and-ovarian-cancer-risk-assessment-minority
  Disease: Breast Cancer|Ovarian Cancer; Type: Data|Program; State: Georgia
• Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features.
  Derkaoui Touria, et al. BMC women's health 2016 10 (1) 68
• "Maybe they have found something new" participants' views on returning cohort psychosocial survey results.
  Bureau Eve et al. Health expectations : an international journal of public participation in health care and health policy 2015 Dec 18(6) 2425-36
• BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18-30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial.
  Kwiatkowski Fabrice et al. Trials 2016 Oct 17(1) 509
• Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.
  Pulford David J et al. BMC medical ethics 2016 Oct 17(1) 63
• New Study Highlights the Benefits of BRCA Testing for All People of Ashkenazi Jewish Descent
  Current Screening Standards May Miss BRCA Carriers with Significant Cancer Risk, Newswise, October 20, 2016
• The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
  Eliade Marie et al. Oncotarget 2016 Oct
• Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
  Zaaijer Leendert H, et al. British journal of cancer 2016 10
• Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.
  Alemar Bárbara, et al. Cancer genetics 2016 9 (9) 417-422

• CDC Information (4)
• CDC-Authored Pub (2)

• Human (52)
• Pathogen (0)

• Human (491)
• Pathogen (0)

• Human (151)
• Pathogen (0)

• Guidelines (7)
• Tier Table (3)
• Synthesis (7)

• Huamn (28)
• Pathogen (0)

Relevant Resources

• Cancer Genomics and Epidemiology Navigator (CGEN)
• Genetics and Genomics Competencies Center (G2C2)
• NIH Genetic Testing Registry
• NIH MedGen Database
• Online Mendelian Inheritance in Man (OMIM)
• PharmGKB